ABSTRACT

Introduction: Short bowel syndrome (SBS) is a clinical condition that can affect childhood and adult patients. Biomarker research is expected to be a new frontier in the clinical application, helpful for patients and health-care systems.

Areas covered: SBS is usually a consequence of a massive intestinal resection that leads to an intestinal failure because of the reduction of absorptive surface, bacterial overgrowth, and faster intestinal transit. This new condition requires a multidisciplinary expertise to achieve again digestive autonomy. Parental nutrition (PN) supports nutritional status in SBS patients while the new guidelines on intestinal transplantation confirm its strict indication only for patients at actual risk of death on PN. A PubMed literature review from the 1980s up to date was performed, highlighting proteomic biomarkers and growth factor therapies that have shown so far promising results in SBS patients.

Expert opinion: Apart from a few specific biomarkers and growth factors, the discovery of specific molecular events is currently under investigation of the proteomic analysis and could potentially represent fundamental, future changes in prevention, diagnosis, therapeutic management, and experimental practices in SBS.

摘要

简介: 短肠综合征 (SBS) 是一种可影响儿童和成人患者的临床疾病。生物标志物研究有望成为临床应用的新前沿，对患者和医疗保健系统都有帮助。

涵盖的领域：SBS 通常是大肠切除术的结果，由于吸收面减少、细菌过度生长和肠道转运加快，导致肠功能衰竭。这种新情况需要多学科专业知识才能再次实现消化自主权。肠外营养 (PN) 支持 SBS 患者的营养状况，而新的肠移植指南确认其严格适应症仅适用于有 PN 实际死亡风险的患者。对 1980 年代至今的 PubMed 文献进行了回顾，重点介绍了迄今为止在 SBS 患者中显示出可喜结果的蛋白质组生物标志物和生长因子疗法。

专家意见：除了一些特定的生物标志物和生长因子外，特定分子事件的发现目前正在蛋白质组学分析中进行调查，并可能代表 SBS 预防、诊断、治疗管理和实验实践的基本、未来变化。